Pooja Bharali

Pooja Bharali


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
PBPooja Bharali
Pooja Bharali
SCSubhash Chand
Subhash Chand
HCHarish Chander
Harish Chander
Background/Objectives: Trastuzumab is an effective therapeutic intervention for treating HER2-positive breast cancers. The cost-effectiveness, global demand, and patent expiration of trastuzumab have led to the inflow of its biosimilars in the global market. With the rise of biosimilars in the biopharmaceutical market, it has become crucial to ensure that the biosimilar is at par with the original monoclonal antibody (mAb)in terms of efficacy, safety, and quality. Bioassay is one of the critical quality attributes (CQAs), hence developing a reliable and robust bioassay is essential for the evaluation of their biological activity and the harmonization of the quality of these biologics, supporting their safe and effective use in clinical practice. Methods: The present study aimed to develop a robust cell-based bioassay to assess the bioactivity of trastuzumab and its biosimilars for quality control testing. For this purpose, molecular characterization of different HER2-positive breast cancer cell lines of SKBR3, BT474, MDA-MD-453, MDA-MB-175, MCF-7, and MDA-MB-231 was performed to select a suitable cell line for the cell-based bioassay. Results: The SKBR3 cell line was found to express the HER2 receptors significantly higher in comparison to the other cell lines, and it was thereby selected for further bioassay optimization. The biological activity of trastuzumab was determined using the inhibition of proliferation (IOP) assay on the SKBR3, which was optimized based on the parameters of cell seeding density, drug dilution range, and incubation time, and it was further validated as per the compendial guidelines and found valid for the parameters of specificity, accuracy (% relative bias = 0.0067%), precision (repeatability: % GCV = 1.21%), linearity (R2 = 0.99), and range (50% to 200%). Additionally, the biological activity of different trastuzumab biosimilars was assessed using the validated IOP assay and compared to the HER2 binding assay performed by flow cytometry. The biological activity of different trastuzumab biosimilars was found to be comparable to the WHO primary reference standard of trastuzumab in terms of its relative potency using the IOP assay and binding assay by flow cytometry. Conclusions: Thus, an economic and robust cell-based bioassay method was successfully developed to assess the bioactivity of trastuzumab and its biosimilars.

9 November 2022 in International Journal of Cancer Management
Verified
Journal Article
Open access
PDF file
AMAbdul Malik
Abdul Malik
PBPrajjalendra Barooah
Prajjalendra Barooah
SSSnigdha Saikia
Snigdha Saikia
SMSubhash Medhi
Subhash Medhi
SKSimanta Kalita
Simanta Kalita
AAAws Alshamsan
Aws Alshamsan
Background: The microRNA (miRNA) mediated translational repression can cause various diseases in humans. The liver-specific miRNA (microRNA-122 (miR-122)) is primarily involved in tissue tropism during hepatitis C virus (HCV) infection which ultimately leads to hepatocellular carcinoma (HCC). Objectives: This study focuses on evaluating host serum miR-122 as a prognostic marker in HCV-induced hepatocellular carcinoma. Methods: Evaluation of miR-122 expression was carried out by quantitative real time PCR. Results: Positive expression of miR-122 was observed in patients with chronic hepatitis C (CHC) followed by HCC patients compared to healthy controls. A difference in median levels of the miR-122 expression in CHC and HCC patients (P < 0.000) was found in contrast to cirrhosis patients (P = 0.511). The serum miR-122 expression was found threefold higher in liver cirrhosis patients than chronic hepatitis. Further, the area under the receiver operating characteristic curve (AUROC) analysis of miR-122 expression profile can efficiently distinguish CHC patients (AUROC = 0.978, P = 0.000, 95% confidence interval (CI) = 0.958 to 0.998) and HCC from healthy controls (AUROC = 0.971, P = 0.000, 95% CI = 0.944 to 0.997). Moreover, receiver operating characteristic (ROC) curve analysis significantly distinguished between CHC patients from cirrhosis patients (AUROC = 0.955, P = 0.000, 95% CI = 0.925 to 0.986) but not CHC from HCC patients (AUROC = 0.584, P = 0.104, 95% CI = 0.485 to 0.684). This study revealed a substantial correlation of miR-122 with HCV viral load (r = 0.56, P = 0.000), ALT (r = 0.67, P = 0.000) and AST (r = 0.65, P = 0.000) levels. Conclusions: Serum miR-122 can potentially serve as a promising prognostic tool for HCV induced HCC.

17 March 2022 in Research Square
Verified
Preprint
Open access
PDF file
AMAbdul Malik
Abdul Malik
PBPrajjalendra Barooah
Prajjalendra Barooah
SSSnigdha Saikia
Snigdha Saikia
SKSimanta Kalita
Simanta Kalita
MKManash Jyoti Kalita
Manash Jyoti Kalita
AAAws Alshamsan
Aws Alshamsan
The features of translational repression by micro-RNA can cause various diseases in humans. The liver-specific microRNA (mir122) is primarily involved in tissue tropism during HCV infection. This study focuses on evaluating host serum miR-122 as a prognostic marker in HCV infection. A positive expression of miR-122 was observed in CHC patients followed by HCC patients compared to healthy controls. A difference in median levels of miR-122 expression in CHC and HCC patients (p < 0.000) was found in contrast to Cirrhosis patients (p = 0.511). The serum miR-122 expression was found threefold higher in liver cirrhosis patients than chronic hepatitis. Further, the AUROC analysis of miR-122 expression profile can efficiently distinguish CHC patients (AUROC = 0.978, p = 0.000, 95% CI = 0.958 to 0.998) and HCC from healthy controls (AUROC = 0.971, p = 0.000, 95% CI = 0.944 to 0.997). Moreover, ROC curve analysis significantly distinguished between CHC patients from Cirrhosis patients (AUROC = 0.955, p = 0.000, 95% CI = 0.925 to 0.986) but not CHC from HCC patients (AUROC = 0.584, p = 0.104, 95% CI = 0.485 to 0.684). This study revealed a substantial correlation of miR-122 with HCV viral load (r = 0.56, p = 0.000), ALT (r = 0.67, p = 0.000) and AST (r = 0.65, p = 0.000) levels. Serum miR-122 can potentially serve as a promising prognostic tool for HCV induced HCC.